Board of Directors

---

Dr. Geffner is currently chief medical officer (CMO) at Immunovant, a biotechnology company developing therapies for patients with various autoimmune diseases. Before joining Immunovant as CMO, he was CMO and head of Product Development for BlueSphere Bio (BSB), with a focus on developing adoptive T-cell therapeutics. 

Prior roles include leading Hematology Clinical Development and Head of Global Medical Affairs at Achillion Pharmaceuticals (now Astra Zeneca). 

Prior to Achillion, he spent 15 years in various senior leadership positions at Schering-Plough/Merck across Clinical Development, Clinical Operations and Medical Affairs. His other prior roles include Head of Anti-Infectives/Hosptial and specialty care Medical Affairs teams, US Medical Affairs Integration lead and Clinical Development Leader. 

Dr. Geffner had dual board certification from the American Board of Pediatrics and the American Board of Psychiatry and Neurology with special competency in Child Neurology. He is a graduate of Albany Medical College and holds an MBA from Fairleigh-Dickinson University. 

Dr. Uknis  is a graduate of Temple University (BA 1986, MD 1990). He is a transplant surgeon trained at the University of Minnesota and has performed pancreas and islet transplantation at Minnesota, Harvard, and the University of Massachusetts. He left clinical surgery in 2007, received his MBA from George Washington University in 2008, and has since held positions of increasing responsibility from Medical Director through Vice President/Chief Medical Officer for small, mid, and large cap Biotechnology companies. He has been a participant in $5.8 Billion total value of acquisitions and mergers since 2008. He has had 2 worldwide marketing authorization approvals for orphan diseases (Cinryze for Hereditary Angioedema and Maribavir for CMV infection in Transplant patients). 

Dr. Recupero has over 20 years of success in strategic leadership and new business development in developing, negotiating, and managing critical path strategic alliances, partnerships, M&A, and licensing agreements for start-up, small, and mid-size (both public and private) biopharma companies. His expertise crosses several therapeutic areas, technologies, and modalities including, immuno-oncology therapeutics, infectious disease vaccines, therapeutic vaccines, oral drug delivery, cell therapy, and gene therapy. Most recently, Dr. Recupero was VP of Business Development at IMUNON and before that led business development teams at Adare Pharmaceuticals, Aptalis Pharma (acquired by Allergan), MaxCyte, and Gene Logic. He did his postdoctoral research in oncology at the Cleveland Clinic and completed his PhD at the University of Cincinnati.